Semaglutide 注射液的适应症是2型糖尿病伴外周动脉疾病间歇性跛行。 此药物由丹麦诺和诺德公司/ 诺和诺德(中国)制药有限公司生产并提出实验申请,[实验的目的] 证明在标准治疗基础上,与安慰剂相比,皮下Semaglutide 1 mg每周一次对2型糖尿病合并伴间歇性跛行的外周动脉疾病患者的行走能力的作用。 文章目录[隐藏] 基本信息...
tennessee nashville 405 university of texas health science center paul schulz 美国 texas houston 406 albuquerque neuroscience inc paula lane 美国 new mexico albuquerque 407 ki health partner llc peter mcallister 美国 connecticut stamford 408 guilford neurologic associates,inc pramod sethi 美国 north ...
Comparative Efficacy and Safety of Resmetirom Versus Semaglutide in Treating MASH and MASLD: A Network Meta-Analysisdoi:10.1097/MJT.0000000000001808Hazem AyeshDivision of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN...
Hazem AyeshEndocrinology Division, Deaconess Clinic, Evansville, INOmolola B. OlajideDepartment of Medicine, Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical Center, Nashville, TNAmerican Journal of TherapeuticsAmerican Journal of Therapeutics...